Lyrdal, David <br/><br/>
Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b.  [electronic resource] 

 -  Acta oncologica (Stockholm, Sweden)  2009 
 - 901-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1651-226X 
<br/><br/><label>Standard No.: </label>10.1080/02841860902795257  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Polyethylene Glycols--therapeutic use<br/>Prognosis<br/>Recombinant Proteins<br/>Risk Factors<br/>Survival Rate<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--metabolism